We envision that such a pharmaceutical would be widely applicable, as a first-line therapy for neuronopathic GD, as a prospective prophylactic agent against GBA1-PD, and, perhaps most broadly impactful, as a potential disease-modifying therapy for sporadic PD [3, 13–15]. The gene discussed is GBA1; the disease is Parkinson disease.